Pediatric Dosing for Bifilac Sachets
For children aged 1-12 years, administer 1 sachet once or twice daily; for infants under 1 year, use is not specifically established in the available FDA labeling, which only provides adult dosing of 1 capsule once or twice daily. 1
Age-Specific Dosing Guidance
Children 1-12 Years
- Standard dose: 1 sachet once or twice daily
- Administration should be under supervision of a licensed medical practitioner 1
- Can be given with or without meals (based on general probiotic administration principles)
Infants Under 1 Year
- No specific pediatric dosing established in the FDA labeling for Bifilac 1
- The product label only specifies "usual adult dose" without pediatric-specific recommendations
- Use requires careful medical supervision given the lack of established infant dosing 1
Important Clinical Considerations
Contraindications and Precautions:
- Contraindicated in patients with known hypersensitivity to any ingredients 1
- Use with caution in children under 18 years of age 1
- Must be administered under licensed medical practitioner supervision 1
- Keep out of reach of children 1
Safety Profile: The evidence for probiotic safety in pediatric populations is generally reassuring. Systematic reviews of probiotics in infants 0-24 months and children up to 18 years show that adverse events are typically unrelated to the probiotic product, with most products being well-tolerated 2, 3. However, safety concerns exist for immunocompromised, chronically debilitated, or seriously ill children with indwelling medical devices 4.
Clinical Context
Bifilac is indicated for clinical dietary management of suboptimal nutritional status and physiologically stressful conditions 1. While one study demonstrated efficacy in acute viral diarrhea in children aged 3 months to 3 years 5, the specific formulation and dosing used in that research may differ from commercially available sachets.
Critical Gap: The FDA labeling does not provide weight-based or age-specific pediatric dosing, which is a significant limitation for clinical practice. Practitioners should consider consulting with pediatric gastroenterology or infectious disease specialists when prescribing to infants, particularly those under 3 months of age.